Inloggen
E-mail
Wachtwoord
Paswoord weergeven
Bewaren
Bent u uw wachtwoord vergeten?
Gratis lid worden
Registreer
Registreer
Instellingen
Instellingen
Dynamische koersen 
OFFON

MERUS N.V.

(MRUS)
OverzichtKoersenGrafiekenNieuwsRatingsAgendaOndernemingFinanciŽnConsensusHerzieningenBeursproducten 
OverzichtAl het nieuwsAanbevelingen van analistenAndere talenPersberichtenOfficiŽle publicatiesSectornieuws
Communiquťs de presse de la sociťtť MERUS N.V.
10/11Merus to Participate in a Fireside Chat at the Jefferies London Healthcare Conference (..
AQ
08/11MERUS N.V. : Entry into a Material Definitive Agreement, Financial Statements and Exhibits..
AQ
05/11Merus Announces Pricing of Public Offering of Common Shares
GL
04/11Merus N.V. Announces Proposed Public Offering of Common Shares
AQ
02/11Merus Announces Regulatory Update on Zenocutuzumab, Financial Results for the Third Qua..
GL
02/11MERUS N.V. Management's Discussion and Analysis of Financial Condition and Results of ..
AQ
07/10MERUS N : Presents Early Clinical Data on MCLA-158 and Preclinical Data on Zenocutuzumab a..
AQ
30/09MERUS N : Announces Poster Presentations on Zenocutuzumab and MCLA-158 at the AACR-NCI-EOR..
AQ
07/09Merus to Participate in Upcoming Investor Conferences
GL
05/08MERUS N : Announces Financial Results for the Second Quarter and Provides Business Update
AQ
05/08MERUS N : Management's Discussion and Analysis of Financial Condition and Results of Opera..
AQ
21/07MERUS N : Announces Publication in Nature Communications on MCLA-145's Novel Mechanism of ..
AQ
07/07Merus to Participate in William Blair's Biotech Focus Conference 2021
GL
04/06Merus Presents Clinical Data on Zenocutuzumab in NRG1-fusion (NRG1+) Cancers at the Ame..
GL
28/05MERUS N.V. : Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Submission o..
AQ
26/05Merus to Participate in a Fireside Chat at the Jefferies Virtual Healthcare Conference
GL
19/05Merus Announces Publication of Abstract on Zenocutuzumab in NRG1-fusion (NRG1+) Cancers..
GL
13/05MERUS N : Announces Collaborations in Israel, Italy and Spain to Increase Screening and Id..
AQ
11/05MERUS N : to Participate in a Fireside Chat at the 2021 RBC Capital Markets Global Healthc..
AQ
06/05Merus Announces Financial Results for the First Quarter and Provides Business Update
GL
06/05MERUS N : Management's Discussion and Analysis of Financial Condition and Results of Opera..
AQ
03/05MERUS N : Announces First Patient Treated in Phase 1/2 Clinical Trial of MCLA-129 in Advan..
AQ
28/04MERUS N : Zenocutuzumab Clinical Data Selected for Oral Presentation at the 2021 American ..
AQ
16/03Merus Announces Financial Results for the Fourth Quarter and Full Year 2020 and Provide..
GL
10/03Merus Announces Poster Presentations for Zenocutuzumab and MCLA-129 at the American Ass..
GL
08/03MERUS N : to Participate in a Fireside Chat at the 33rd Annual Roth Conference
AQ
01/02Merus to Participate in Upcoming Investor Conferences
GL
21/01Merus Announces Pricing of Public Offering of Common Shares
GL
19/01Merus N.V. Announces Proposed Public Offering of Common Shares
GL
19/01MERUS N : Lilly and Merus NV Announce Collaboration to Discover Novel T-Cell Re-Directing ..
PR
12/01Merus Announces Collaborations with Nationwide Medical Organizations in the Netherlands..
GL
12/01MERUS N : Announces Presentation of Phase 1 Clinical Data for MCLA-158 at the American Soc..
AQ
11/01Merus Announces Presentation of Phase 1 Clinical Data for MCLA-158 at the American Soci..
GL
07/01MERUS N : Granted FDA Fast Track Designation of Zenocutuzumab for the Treatment of Patient..
AQ
2020MERUS N : and Sema4 Enter Into an Agreement to Support ' Phase 1/2 Clinical Trial of Zenoc..
AQ
2020MERUS N : and Sema4 Enter Into an Agreement to Support†' Phase 1/2 Clinical Trial of Zenoc..
AQ
2020MERUS N : to Present at the Jefferies Virtual London Healthcare Conference
AQ
2020MERUS N : to Present at the Jefferies Virtual London Healthcare Conference
AQ
2020MERUS N : Announces Poster Presentations on MCLA-145 at Society for Immunotherapy of Cance..
AQ
2020Merus Announces Poster Presentations on MCLA-145 at Society for Immunotherapy of Cancer
GL
2020MERUS N : Announces Financial Results for the Third Quarter and Provides Business Update
AQ
2020Merus Announces Financial Results for the Third Quarter and Provides Business Update
GL
2020MERUS N : and myTomorrows Announce Expansion of Collaboration for Screening and eNRGy Clin..
AQ
2020MERUS N : and myTomorrows Announce Expansion of Collaboration for Screening and eNRGy Clin..
AQ
2020Merus and myTomorrows Announce Expansion of Collaboration for Screening and eNRGy Clini..
GL
2020MERUS N : to Present at the 2020 Wedbush PacGrow Healthcare Conference
AQ
2020Merus to Present at the 2020 Wedbush PacGrow Healthcare Conference
GL
2020Merus Announces Financial Results for the Second Quarter and Provides Business Update
GL
2020Merus Appoints Andrew Joe, M.D., as Chief Medical Officer
GL
2020Merus announces FDA Orphan Drug Designation of Zenocutuzumab for the Treatment of Pancr..
GL
2020Merus and Caris Life Sciences Announce Collaboration to Detect NRG1 Fusions in Cancer P..
GL
2020Merus to Participate in Fireside Chat at the Jefferies Virtual Healthcare Conference
GL
2020Merus Announces the Acceptance of Six Abstracts at Upcoming Medical Conferences and Pro..
GL
2020Merus Announces Financial Results for the First Quarter and Provides Business Update
GL
2019Merus Announces Chief Executive Officer Transition
GL
2019Merus Announces Financial Results for the Third Quarter 2019 and Provides Business Upda..
GL
2019Merus Announces Pricing of Public Offering of Common Shares
GL
2019Merus Bispecific Antibody MCLA-128 Shows Encouraging Early Clinical Activity in Patient..
GL
2019Merus Announces Presentation and Poster on MCLA-128 and MCLA-129 Programs at the AACR-N..
GL
2019Merus Announces Financial Results for the Second Quarter 2019 and Provides Business Upd..
GL
2019Merus to Present at the Jefferies 2019 Healthcare Conference
GL
2019Merus to Present at the RBC Capital Markets 2019 Healthcare Conference
GL
2019MERUS : ProBioGen's GlymaxXģ ADCC Enhancement Technology Used by Betta Pharmaceuticals
PR
2018Merus Announces Financial Results for the Third Quarter 2018 and Provides Business Upda..
GL
2018Merus Announces Global Settlement and End to All Patent Litigation with Regeneron Pharm..
GL
2018Merus to Participate in Citi's 13th Annual Biotech Conference
GL
2018Merus Announces Recent Corporate Developments and Financial Results for the First Quart..
GL
2018Merus Announces Annual Meeting of Shareholders
GL
2018Merus to Report Full Year 2017 Financial Results and Corporate Developments on April 26..
GL
2018Merus and the Vall d'Hebron Institute of Oncology Announce Research Collaboration to De..
GL
2018Merus' Intellectual Property Portfolio Expands with Two New Patents
GL
2018Merus Announces $55.8 Million Private Placement Offering of Common Stock
GL
2017Merus to Present at the Jefferies London Healthcare Conference
GL
2017Merus to Participate in the BIO Investor Forum
GL
2017Merus' Intellectual Property Portfolio Expands with Two New Patents For its Biclonicsģ ..
GL
1  2Volgende